Evidence for continuous glucose monitoring: sufficient for reimbursement?

Evidence for continuous glucose monitoring is mounting. Meta-analyses consistently show lowering of HbA1c , and the first trial reporting a reduction in severe hypoglycaemic events in patients with hypoglycaemia unawareness has recently been presented. The more recent trials studied larger numbers of patients and may have shown better results because of improved technology. The various combinations of pump and sensor, with automated bolus calculators and low glucose suspend features, make evaluation more challenging from a reimbursement point of view, but evidence seems convincing enough to justify reimbursement for selected patient groups, including those who have shown a substantial improvement in HbA1c during a trial period, and those with hypoglycaemia unawareness who encountered severe hypoglycaemia in the recent past. More data on cost-efficacy are needed. This article is protected by copyright. All rights reserved